Stanley Laman Group, Ltd. Aeglea Bio Therapeutics, Inc. Transaction History

Stanley Laman Group, Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 30, 2018	SELL	$8.24 - $11.0 $288,696 - $385,396	-35,036 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$7.87 - $10.89 $181,757 - $251,504	23,095 Added 193.41%	35,036 $371,000
Q1 2018 May 01, 2018	BUY	$5.07 - $10.9 $60,540 - $130,156	11,941 New	11,941 $118,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.